References
Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34:462–8.
Bonvalot S, Cozic N, Le Cesne A, et al. Initial active surveillance strategy for patients with peripheral sporadic primary desmoid-type fibromatosis: A multicentric phase 2 observational trial. Ann Surgic Oncol. 2023. https://doi.org/10.1245/s10434-023-14341-2.
Colombo C, Fiore M, Grignani G, et al. A prospective observational study of active surveillance in primary desmoid fibromatosis. Clin Cancer Res. 2022;28(18):4027–32.
Schut AW, Timbergen MJM, van Broekhoven DLM, et al. A nationwide prospective clinical trial on active surveillance in patients with non-intra-abdominal desmoid-type fibromatosis: The GRAFITI trial. Ann Surg. 2023;277(4):689–96.
Gounder MM, Mahoney MR, Van Tine BA, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med. 2018;379:2417–28.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
The authors declare no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bonvalot, S., Watson, S. ASO Author Reflections: Active Surveillance and Desmoid. Ann Surg Oncol 30, 8669–8670 (2023). https://doi.org/10.1245/s10434-023-14411-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-023-14411-5